What makes 2025 structurally different from prior years is the simultaneous convergence of federal litigation (the FTCs insulin-pricing lawsuit against all three Big Three PBMs), landmark state legislation (Arkansas banning PBM ownership of in-state pharmacies, effective 2026), and bipartisan congressional proposals (the Patients Before Monopolies Act) that would mandate structural separation between PBM and pharmacy assets
Key trials include a 2017 phase 2 study of exenatide showing modest motor improvements, and the 2024 LIXIPARK study demonstrating lixisenatide benefits on motor function
D., Raczniak T
By reducing the overall "inflammatory load" in the gut, glutathione helps create a habitat where your microbiome can remain diverse and resilient
Melanotan 2 is not FDA approved for any medical or cosmetic use
The deal was announced in early November, and most analyst notes so far focus on pricing, eligibility, and timelines rather than revised line-item revenue forecasts
